Lucia Altucci is an Associate Professor at the Second University of Naples. She has a specialisation in Medical oncology and a PhD in Molecular Pathology applied to cancer research. She is the Editor of the Medecine in Focus section of the international J of Biochemistry and Cell Biology (IF 3.9). She has focus her research on signal transduction in biological systems with the focus on mechanism(s) of differentiation and apoptosis by retinoid & rexinoid receptors and by epigenetic drugs in cancer systems.

flukonazol Flukonazol
Uwolnij się od infekcji płciowych – przywróć radość życia!

doksycyklina Doksycyklina
Nie zwlekaj – przywróc pewność siebie w sypialni już dziś!

n the last years, the induction of differentiation and cell death regulated by epigenetic modulators such as HDACis and HMTis alone or in combination with other agents has been focalized as well as the identification of new epidrugs. To the respect a new international patent application DV 01041-01 has been deposited.She has contributed to the identification and characterisation of a novel RAR-independent signaling pathway involving a crosstalk between PKA and RXR agonists in leukemia and to the discovery of a novel role of RXR in the induction of a default apoptosis pathway in immature leukemia cells. She has been involved as well in the identification and characterisation of the survival and apoptogenic programs induced by retinoic acid in acute promyelocytic leukemia. And she has identificatified and characterized TRAIL as a key molecular and biological target of epigenetic drugs. Related to CANCERDIP, our strategy will offer a comprehensive view of DNA methylation and a general understanding on its role for gene deregulation in leukemias. We will i) highlight the role of methylation as causal process in leukemia, ii) define the methylation patterns deregulated, iii) investigate whether sensitive and specific analysis of global DNA methylation can indicate diagnostic or prognostic markers of disease, iv) investigate the influence of frequently occurring translocations, v) study in terms of methylation modifications the evolutions from normal to preneoplastic diseases and to AML, vi) verify if and which DNA methylation patterns could serve as reliable markers for MRD quantitation and as a predictor for leukemia relapse in remission; vii) characterize whether the analysis of methylation levels in clinical remission can be proposed as a biomarker for patients’relapse risk. This approach will allow the identification and the characterisation of methylation patterns which could be exploited for therapeutic studies.

See: Patologia Generale UNINA2
  Lucia Altucci



Lucia Altucci
| CANCERDIP is funded under the European Commission's 7th Framework Programme for Research and Technological Development |
The Use of MeDip in Cancer for Better Clinical Management